Evaluating Vitamin D Repletion Regimens and Effects in Veteran Patients

Sheryl Aterrado, Gregory Ono, Shawn Kanehira-Mar, Joy Meier, Arthur L Swislocki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND: There are wide variations in recommended dosing for vitamin D repletion. The identification of specific dosing thresholds to optimize repletion of 25-hydroxyvitamin D3 (also known as 25(OH)D) may help narrow the wide spectrum of vitamin D dosing.

OBJECTIVE: The primary objective of this study was to evaluate vitamin D treatment regimens and their dose response effect on vitamin D serum levels. Secondary outcomes include evaluation of the frequency of monitoring vitamin D serum levels and prescription adherence.

METHODS: This was a multicenter, retrospective data extraction analysis conducted in patients who initiated monotherapy of ergocalciferol and cholecalciferol between January 1, 2005 and December 31, 2010. Following vitamin D therapy initiation, changes in laboratory values, frequency of laboratory monitoring, and prescription adherence were assessed. Ergocalciferol and cholecalciferol groups were separately organized into quartiles to identify dosing ranges that had the most impact on changes in 25(OH)D laboratory values.

RESULTS: There were 2272 and 4140 monotherapy patients in the ergocalciferol and cholecalciferol groups, respectively. Cholecalciferol mean doses between 600 and 1100 IU had similar changes in 25(OH)D ranging from 8 to 9.1 ng/mL. Cholecalciferol mean doses of 2700 IU had 12.7 ng/mL 25(OH)D increase (P < 0.05). Ergocalciferol at mean doses of 11 000 IU had a 19.9 ng/mL increase of 25(OH)D (P < 0.05). At baseline 25(OH)D levels less than 15 ng/mL, 90% of subjects reached a therapeutic 25(OH)D level with a cumulative 300 000 IU cholecalciferol dose. Adherence, calculated by medication possession ratio, was greater with cholecalciferol than ergocalciferol (87% compared with 68%).

CONCLUSIONS: Lower vitamin D dose ranges had a comparable effect on 25(OH)D change. Higher doses can produce higher levels, but the relationship is not linear.

Original languageEnglish (US)
Pages (from-to)969-977
Number of pages9
JournalAnnals of Pharmacotherapy
Volume49
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Cholecalciferol
Veterans
Vitamin D
Ergocalciferols
Prescriptions
Calcifediol
Medication Adherence
Serum
Therapeutics

Keywords

  • adherence
  • cholecalciferol
  • ergocalciferol
  • medication possession ratio
  • vitamin D

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Evaluating Vitamin D Repletion Regimens and Effects in Veteran Patients. / Aterrado, Sheryl; Ono, Gregory; Kanehira-Mar, Shawn; Meier, Joy; Swislocki, Arthur L.

In: Annals of Pharmacotherapy, Vol. 49, No. 9, 01.09.2015, p. 969-977.

Research output: Contribution to journalArticle

Aterrado, Sheryl ; Ono, Gregory ; Kanehira-Mar, Shawn ; Meier, Joy ; Swislocki, Arthur L. / Evaluating Vitamin D Repletion Regimens and Effects in Veteran Patients. In: Annals of Pharmacotherapy. 2015 ; Vol. 49, No. 9. pp. 969-977.
@article{65476cff52a64af0b8325d32cd0999b7,
title = "Evaluating Vitamin D Repletion Regimens and Effects in Veteran Patients",
abstract = "BACKGROUND: There are wide variations in recommended dosing for vitamin D repletion. The identification of specific dosing thresholds to optimize repletion of 25-hydroxyvitamin D3 (also known as 25(OH)D) may help narrow the wide spectrum of vitamin D dosing.OBJECTIVE: The primary objective of this study was to evaluate vitamin D treatment regimens and their dose response effect on vitamin D serum levels. Secondary outcomes include evaluation of the frequency of monitoring vitamin D serum levels and prescription adherence.METHODS: This was a multicenter, retrospective data extraction analysis conducted in patients who initiated monotherapy of ergocalciferol and cholecalciferol between January 1, 2005 and December 31, 2010. Following vitamin D therapy initiation, changes in laboratory values, frequency of laboratory monitoring, and prescription adherence were assessed. Ergocalciferol and cholecalciferol groups were separately organized into quartiles to identify dosing ranges that had the most impact on changes in 25(OH)D laboratory values.RESULTS: There were 2272 and 4140 monotherapy patients in the ergocalciferol and cholecalciferol groups, respectively. Cholecalciferol mean doses between 600 and 1100 IU had similar changes in 25(OH)D ranging from 8 to 9.1 ng/mL. Cholecalciferol mean doses of 2700 IU had 12.7 ng/mL 25(OH)D increase (P < 0.05). Ergocalciferol at mean doses of 11 000 IU had a 19.9 ng/mL increase of 25(OH)D (P < 0.05). At baseline 25(OH)D levels less than 15 ng/mL, 90{\%} of subjects reached a therapeutic 25(OH)D level with a cumulative 300 000 IU cholecalciferol dose. Adherence, calculated by medication possession ratio, was greater with cholecalciferol than ergocalciferol (87{\%} compared with 68{\%}).CONCLUSIONS: Lower vitamin D dose ranges had a comparable effect on 25(OH)D change. Higher doses can produce higher levels, but the relationship is not linear.",
keywords = "adherence, cholecalciferol, ergocalciferol, medication possession ratio, vitamin D",
author = "Sheryl Aterrado and Gregory Ono and Shawn Kanehira-Mar and Joy Meier and Swislocki, {Arthur L}",
year = "2015",
month = "9",
day = "1",
doi = "10.1177/1060028015591034",
language = "English (US)",
volume = "49",
pages = "969--977",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "9",

}

TY - JOUR

T1 - Evaluating Vitamin D Repletion Regimens and Effects in Veteran Patients

AU - Aterrado, Sheryl

AU - Ono, Gregory

AU - Kanehira-Mar, Shawn

AU - Meier, Joy

AU - Swislocki, Arthur L

PY - 2015/9/1

Y1 - 2015/9/1

N2 - BACKGROUND: There are wide variations in recommended dosing for vitamin D repletion. The identification of specific dosing thresholds to optimize repletion of 25-hydroxyvitamin D3 (also known as 25(OH)D) may help narrow the wide spectrum of vitamin D dosing.OBJECTIVE: The primary objective of this study was to evaluate vitamin D treatment regimens and their dose response effect on vitamin D serum levels. Secondary outcomes include evaluation of the frequency of monitoring vitamin D serum levels and prescription adherence.METHODS: This was a multicenter, retrospective data extraction analysis conducted in patients who initiated monotherapy of ergocalciferol and cholecalciferol between January 1, 2005 and December 31, 2010. Following vitamin D therapy initiation, changes in laboratory values, frequency of laboratory monitoring, and prescription adherence were assessed. Ergocalciferol and cholecalciferol groups were separately organized into quartiles to identify dosing ranges that had the most impact on changes in 25(OH)D laboratory values.RESULTS: There were 2272 and 4140 monotherapy patients in the ergocalciferol and cholecalciferol groups, respectively. Cholecalciferol mean doses between 600 and 1100 IU had similar changes in 25(OH)D ranging from 8 to 9.1 ng/mL. Cholecalciferol mean doses of 2700 IU had 12.7 ng/mL 25(OH)D increase (P < 0.05). Ergocalciferol at mean doses of 11 000 IU had a 19.9 ng/mL increase of 25(OH)D (P < 0.05). At baseline 25(OH)D levels less than 15 ng/mL, 90% of subjects reached a therapeutic 25(OH)D level with a cumulative 300 000 IU cholecalciferol dose. Adherence, calculated by medication possession ratio, was greater with cholecalciferol than ergocalciferol (87% compared with 68%).CONCLUSIONS: Lower vitamin D dose ranges had a comparable effect on 25(OH)D change. Higher doses can produce higher levels, but the relationship is not linear.

AB - BACKGROUND: There are wide variations in recommended dosing for vitamin D repletion. The identification of specific dosing thresholds to optimize repletion of 25-hydroxyvitamin D3 (also known as 25(OH)D) may help narrow the wide spectrum of vitamin D dosing.OBJECTIVE: The primary objective of this study was to evaluate vitamin D treatment regimens and their dose response effect on vitamin D serum levels. Secondary outcomes include evaluation of the frequency of monitoring vitamin D serum levels and prescription adherence.METHODS: This was a multicenter, retrospective data extraction analysis conducted in patients who initiated monotherapy of ergocalciferol and cholecalciferol between January 1, 2005 and December 31, 2010. Following vitamin D therapy initiation, changes in laboratory values, frequency of laboratory monitoring, and prescription adherence were assessed. Ergocalciferol and cholecalciferol groups were separately organized into quartiles to identify dosing ranges that had the most impact on changes in 25(OH)D laboratory values.RESULTS: There were 2272 and 4140 monotherapy patients in the ergocalciferol and cholecalciferol groups, respectively. Cholecalciferol mean doses between 600 and 1100 IU had similar changes in 25(OH)D ranging from 8 to 9.1 ng/mL. Cholecalciferol mean doses of 2700 IU had 12.7 ng/mL 25(OH)D increase (P < 0.05). Ergocalciferol at mean doses of 11 000 IU had a 19.9 ng/mL increase of 25(OH)D (P < 0.05). At baseline 25(OH)D levels less than 15 ng/mL, 90% of subjects reached a therapeutic 25(OH)D level with a cumulative 300 000 IU cholecalciferol dose. Adherence, calculated by medication possession ratio, was greater with cholecalciferol than ergocalciferol (87% compared with 68%).CONCLUSIONS: Lower vitamin D dose ranges had a comparable effect on 25(OH)D change. Higher doses can produce higher levels, but the relationship is not linear.

KW - adherence

KW - cholecalciferol

KW - ergocalciferol

KW - medication possession ratio

KW - vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84953344460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953344460&partnerID=8YFLogxK

U2 - 10.1177/1060028015591034

DO - 10.1177/1060028015591034

M3 - Article

VL - 49

SP - 969

EP - 977

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 9

ER -